CHYM vs MANH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CHYM shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Mixed signals with both opportunities and risks present.
MANH exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptional ROE of 71.66%, though it lacks an Altman Z-Score for bankruptcy risk assessment. While the company has a stellar 25-quarter track record of earnings beats, the stock is currently in a severe technical downtrend, losing over 37% of its value in the last six months. The current price of $126.11 trades at a significant premium to both the Graham Number ($20.64) and the growth-based Intrinsic Value ($79.74). Despite a bullish analyst target of $208.55, the combination of slow revenue growth (5.7%) and bearish insider sentiment warrants a neutral stance until price stabilization occurs.
Compare Another Pair
Related Comparisons
CHYM vs MANH: Head-to-Head Comparison
This page compares Chime Financial, Inc. (CHYM) and Manhattan Associates, Inc. (MANH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.